UNASSIGNED: @entity2 is the most common @entity5 in the world. @entity2 is also the most common cause of @entity204 caused by @entity5 worldwide with fatality rate (the overall ratio of mortality to incidence) of 0.87. Nowadays, cure can be achieved only in @entity66 stages using surgical resection or radical radiotherapy. This approach can be considered only in 20% of @entity1 . Outcome of therapy of loco-regionally advanced or @entity2 are unsatisfactory. Despite improvement of radiotherapy techniques, despite introduction of new cytostatics and new targeted therapies, long-term disease control could be achieved only in minority of @entity1 . Immunotherapy is a therapeutic approach which uses the immune system itself against @entity5 . This article is a summary of the authors 17-year experience with different immunotherapeutic agents. It will be focused on big anti- @entity5 vaccines trials START and MAGRIT, and especially trials in the upcoming era of checkpoint inhibitors. Future perspectives of immunotherapy and its combination of recent therapeutic approaches will be considered.Key words: @entity2 - immunotherapy - vaccines - immune checkpoint inhibitors - programmed cell @entity204 protein 1The author declares he has no potential conflicts of interest concerning drugs, products, or   services used in the study.The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.Submitted: 27. 7. 2015Accepted: 27. 10. 2015.

[Present Experience and Perspectives of Immunotherapy of XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity66 :: ('MESH:D004194', 'Disease') :: ['early disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity2 :: ('MESH:D008175', 'Disease') :: ['metastatic lung cancer', 'Lung cancer', 'lung cancer'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity2 :: (MESH:D008175,Disease) :: ['Lung Cancer']
